Vorinostat Completed Phase 2 Trials for Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS) Treatment

Indications	Status	Purpose	Phase
DBCOND0032540 (Leukemia Acute Myeloid Leukemia (AML)) DBCOND0032544 (Myelodysplastic Syndromes (MDS))	Completed	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
NCT00656617	Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)	Cytarabine (DB00987) Vorinostat (DB02546) Idarubicin (DB01177)